Evidence-Based Reviews

Pharmacologic management of autism spectrum disorder: A review of 7 studies

Author and Disclosure Information

 

References

2. Gabis LV, Ben-Hur R, Shefer S, et al. Improvement of language in children with autism with combined donepezil and choline treatment. J Mol Neurosci. 2019;69(2):224-234.

Gabis et al5 examined the safety and efficacy of utilizing donepezil, an acetylcholinesterase inhibitor, plus a choline supplement to treat both core features and associated symptoms in children and adolescents with ASD.

Study design

  • This 9-month randomized, double-blind trial included 60 children/adolescents with ASD who were randomly assigned to receive placebo or donepezil plus a choline supplement. Participants underwent a baseline evaluation (E1), 12 weeks of treatment and re-evaluation (E2), 6 months of washout, and a final evaluation (E3).
  • The baseline and final evaluations assessed changes in language performance, adaptive functioning, sleep habits, autism severity, clinical impression, and intellectual abilities. The evaluation after 12 weeks of treatment (E2) included all of these measures except intellectual abilities.

Outcomes

  • Patients treated with donepezil plus a choline supplement had significant improvement in receptive language skills between E1 and E3 (P = .003).
  • Patients treated with donepezil plus a choline supplement had significant worsening in scores on the Autism Treatment Evaluation Checklist (ATEC) health/physical behavior subscale between E1 and E2 (P = .012) and between E1 and E3 (P = .021).
  • Improvement in receptive language skills was significant only in patients age 5 to 10 years (P = .047), whereas worsening in ATEC health/physical behavior subscale score was significant only in patients age 10 to 16 years (P = .024).
  • Patients treated with donepezil plus a choline supplement reported higher percentages of gastrointestinal disturbance when compared with placebo (P = .007), and patients in the adolescent subgroup had a significant increase in irritability (P = .035).

Conclusion

  • Patients age 5 to 10 years treated with donepezil plus a choline supplement exhibited improved receptive language skills. This treatment was less effective in patients age >10 years, and this group also exhibited behavioral worsening.
  • Gastrointestinal disturbances were the main adverse effect of treatment with donepezil plus a choline supplement.

Continue to: The persistence of excitatory...

Pages

Recommended Reading

Common newborn hearing test promising for early detection of autism
MDedge Psychiatry
COVID-19 cases in children continue to set records
MDedge Psychiatry
Immunodeficiency strongly linked to mental illness, suicidal behavior
MDedge Psychiatry
P3SONG: Evaluation for autism spectrum disorder
MDedge Psychiatry
Obesity, hypoxia predict severity in children with COVID-19
MDedge Psychiatry
Infant’s COVID-19–related myocardial injury reversed
MDedge Psychiatry
Rap music mention of mental health topics more than doubles
MDedge Psychiatry
Kennedy, NIMH demand urgent action on COVID-19 mental health toll
MDedge Psychiatry
To vape or not to vape: Is that really a question?
MDedge Psychiatry
Nicotine vaping tapers off among teens
MDedge Psychiatry